At a glance
ClinicalIndex Comparison Record- ✓Histologically proven invasive cervical carcinoma (squamous cell, adenosquamous, or adenocarcinoma)
- ✓TNM stage IIIB or IVA (FIGO stage IB, IIA, IIB, IIIA, IIIB, or IVA)
- ✓Cytologically or histologically proven metastases to para-aortic lymph nodes
- ✓No more than 8 weeks since diagnosis
- ✕Prior cytotoxic chemotherapy for this or any other malignancy
- ✕Prior radiotherapy for this or any other malignancy, including prior pelvic or abdominal radiation
- ✕Metastases to scalene nodes, intraperitoneal metastases, or metastases to organs outside the radiation field
- ✕Positive chest CT (evidence of thoracic metastases)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study of Extended Field Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients Cervical Carcinoma Metastatic to the Para-Aortic Lymph Nodes
In Brief
A Phase 1 clinical trial evaluating cisplatin, paclitaxel, and 2 other interventions for Cervical Cancer. Completed, enrolled 29 participants across 13 sites.
Detailed Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Paclitaxel and cisplatin may increase the effectiveness of radiation therapy by making the tumor cells more sensitive to the radiation. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of paclitaxel when given with radiation therapy and cisplatin and to see how well they work in treating patients with cancer of the cervix that has spread to the lymph nodes in the pelvis and abdomen.